Stacy Enxing Seng

Venture Partner
Lightstone Ventures

Stacy Enxing Seng is a venture partner with Lightstone Ventures in Menlo Park, CA and a member of the board of directors for Hill-Rom and Sonova AG. Additionally, she is the board chair for Cala Health and also serves with privately held PreCARDIA and the educational nonprofit, The Fogarty Institute for Innovation. Enxing Seng has also held independent director roles with successfully transacted Claret Medical (Boston Scientific), Spirox Inc. (St. Jude) and CVI (Royal Phillips), as well as privately held FIRE 1 and Solace Therapeutics.

Enxing Seng has spent the last 30 years in med-tech with a proven track record for leading technologies and companies from early concept and development through global market leadership. Prior to refocusing her contributions to board of director and venture work, she served as president of Covidien’s vascular business. Enxing Seng joined Covidien through the $2.6 billion ev3 acquisition where in 2001 she was a founding member and executive officer responsible for leading ev3’s peripheral vascular division from inception. Prior to ev3, she also held various positions at other high profile med-tech organizations including Boston Scientific, SCIMED Life Systems, Baxter Healthcare and AmericanHospital Supply.

Enxing Seng is a frequent speaker and panelist at healthcare industry events as well as events focused on authentic leadership, building vibrant, winning cultures and owning your career. She especially enjoys addressing these topics in the context of women’s leadership, communication and empowerment. She has been named as both one of the Top 100 Women in Business and Favorite Role Models for Women in Business in Minnesota.

Enxing Seng earned a Master of Business Administration degree from Harvard University and a bachelor’s degree in public policy from Michigan State University.